SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq:
CRYO), a medical device company focused on the treatment of cardiac
arrhythmias, announced today that Edward F. Brennan, President and Chief
Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, are
scheduled to present at the Roth Capital Partners New York Conference in
New York, NY on Thursday, September 7, 2006 at 1:30 p.m. EDT at The Westin
New York at Times Square.
A live Web cast and recording of the presentation will be available
online from the investor relations page of the Company's corporate Web site
at http://www.cryocor.com. The recording will remain available on CryoCor's
Web site for at least 30 days following presentation.
About CryoCor
CryoCor is a medical technology company that has developed and
manufactures a disposable catheter system based on its proprietary
cryoablation technology for the minimally invasive treatment of cardiac
arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation
System, or the Cryoablation System, is designed to treat cardiac
arrhythmias through the use of cryoenergy, or extreme cold, to destroy
targeted cardiac tissue. The Cryoablation System has been approved in
Europe for the treatment of AF and AFL, the two most common and difficult
to treat arrhythmias, since 2002. In the United States, CryoCor is
conducting a pivotal trial to evaluate the safety and efficacy of the
Cryoablation System for the treatment of AF. In addition, the Company has
conducted a pivotal trial for the treatment of AFL and filed a PMA with the
FDA in 2005. The FDA did not approve that PMA filing for the treatment of
AFL and CryoCor expects to submit an amendment to its PMA with additional
information on safety and effectiveness of the device. For more information
please visit the Company's website at http://www.cryocor.com.
Forward Looking Statements
The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements included in this press release
related to CryoCor's proposed amendment to its PMA for AFL including
CryoCor's timing for such amendment, the possibility of receiving approval
from the FDA for the use of its Cryoablation System to treat AFL and AF,
and the safety of the Cryoablation System versus heat-based ablation
devices, all of which are prospective. Such statements are only predictions
and reflect the Company's expectations and assumptions as of the date of
this press release based on currently available operating, financial, and
competitive information. The actual events or results may differ materially
from those projected in such forward-looking statements due to a number of
factors, including risks involved with the Company's ability to access
additional financing when and to the extent necessary and obtain regulatory
approval in the United States for its Cardiac Cryoablation System for use
in treating AFL and AF within its anticipated timeframes, if at all; risks
associated with the Company's ability to amend its PMA for AFL and
ultimately receive approval from the FDA for the use of its Cryoablation
System to treat AFL; risks associated with the Company's ability to
successfully commercialize its Cardiac Cryoablation System in the United
States and elsewhere if its Cardiac Cryoablation System is approved for use
in the United States; risks associated with the Company's dependence on
patents and proprietary rights; risks associated with the Company's
protection and enforcement of its patents and proprietary rights; risks
associated with the development or availability of competitive products or
technologies; and the other risks and uncertainties identified in the
Company's filings with the Securities and Exchange Commission. These
forward- looking statements speak only as of the date hereof. The Company
expressly disclaims any intent or obligation to update any of these
forward-looking statements.
Contacts:
CryoCor The Ruth Group
Gregory J. Tibbitts Stephanie Carrington / Nick Laudico (investors)
Chief Financial Officer (646) 536-7017 / 7030
(858) 909-2200 scarrington@theruthgroup.com
gtibbitts@cryocor.com nlaudico@theruthgroup.com
Jason Rando (media)
(646) 536-7025
jrando@theruthgroup.com
SOURCE CryoCor, Inc.
 back to top
Related links:
http://www.cryocor.com
CONTACT:
Gregory J. Tibbitts, Chief Financial Officer
of CryoCor, Inc., +1-858-909-2200, gtibbitts@cryocor.com; or
Stephanie Carrington, +1-646-536-7017,
scarrington@theruthgroup.com, or Investors: +1-646-536-7030,
nlaudico@theruthgroup.com, or Media: Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com, all of The Ruth Group,
for CryoCor, Inc.
|
